A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

NCT06469879 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

358

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer Limited Stage

Interventions

DRUG: TQB2450+Anlotinib
DRUG: TQB2450 placebo + Anlotinib placebo

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.